| 中文名称 | 甲苯咪唑 |
|---|---|
| 中文别名 | 甲苯咪唑;(5-苯甲酰-1-苯并咪唑-2-基)氨基甲酸甲酯;二苯酮胍甲酯;甲苯达唑;5-苯甲醯-2-苯并咪唑胺甲酸甲酯;甲苯哒唑;印楝油;2-[(2-氟苄基)氧基]苯甲醛;WAKO130-15201甲苯达唑标准品;甲苯达唑 USP标准品;甲苯咪唑 EP标准品;甲苯咪唑(MEB) 标准品;甲苯咪唑标准品;甲苯咪唑多形体C;甲苯咪唑片;甲苯咪唑系统适应性 EP标准品;5-苯甲酰-2-苯并咪唑胺甲酸甲酯;N-(5-苯甲酰-1H-苯并咪唑-2-基)氨基甲酸甲酯;[5-(苯甲酰基)苯并咪唑-2-基]氨基甲酸甲酯;甲苯达唑系统适用性标准品 |
| 英文名称 | Mebendazole |
| 英文别名 | Mebendazole;(5-Benzoyl-1H-benzimidazol-2-yl)carbamicacidmethylester;(5-benzoyl-1h-benzimidazol-2-yl)-carbamicacidmethylester;(5-benzoyl-1h-benzimidazol-2-yl)-carbamicacimethylester;5-benzoyl-2-benzimidazolecarbamicacimethylester;bantenol;besantin;lomper;mbdz;5-benzoyl-1H-benzimidazol-2-yl carbamic acid methyl ester;5-benzoyl-2-benzimidazolecarbamic acid methyl ester;mebenvet;Mebex;methyl (5-benzoyl-1H-benzimidazol-2-yl)carbamate(SALTDATA: FREE);Methyl (5-benzoyl-1H-benzo[d]imidazol-2-yl)carbamate;Methyl [5-(Benzoyl)benzimidazol-2-yl]carbamate;noverme;telmin;vermox;methyl 5-benzoylbenzimidazol-2-ylcarbamate;5-Benzoyl-2-benzimidazolylcarbamic acid methyl ester;Methyl 5-benzoyl benzimidazole-2-carbamate;BSPBio_000233;BRD-K77987382-001-08-2;Mebendazol (INN-Spanish);NCGC00021698-06;Probes2_000149;MEBENDAZOLE [VANDF];MEBENDAZOLE [ORANGE BOOK];Mebendazol [INN-Spanish];Mebendazole, United States Pharmacopeia (USP) Reference Standard;MEBENDAZOLE [INN];Mebendazole,(S);DTXSID4040682;DB00643;AB00052203;Methyl N-(5-benzoyl-2-benzimidazolyl)carbamate;Pantelmin;(5-Benzoyl-1H-benzimidazol-2-yl)carbamic acid methyl ester;Mebendazole, European Pharmacopoeia (EP) Reference Standard;KBioSS_001778;Mebendazol;CHEBI:6704;SMR000036734;W-106901;SPBio_001442;MEBENDAZOLE [GREEN BOOK];P02CA01;V95;AS-12272;Telmin Equine Wormer;methyl 5-benzoyl-1H-benzo[d]imidazol-2-ylcarbamate;KBioGR_000712;HSDB 3232;MEBENDAZOLE (MART.);KBio2_004346;MEBENDAZOLE (EP MONOGRAPH);NS00008616;Z234895185;SPECTRUM1501110;NCGC00016806-07;Oprea1_768530;UNII-81G6I5V05I;HMS502F13;HMS3604N11;methyl N-(6-benzoyl-1H-1,3-benzodiazol-2-yl)carbamate;Telmintic Powder;NCGC00021698-07;MLS006011879;Mebendazolum [INN-Latin];Mebendazolum (INN-Latin);Prestwick0_000217;Equivurmp Plus;Telmin Syringe Formula;HMS1921F03;HY-17595;Methyl 5-benzoyl-2-benzimidazolecarbamate;BRD-K77987382-001-06-6;Prestwick1_000217;NCGC00016806-13;Tox21_110620;Carbamic acid, (5-benzoyl-1H-benzimidazol-2-yl)-, methyl ester;BSPBio_003178;SR-01000003109;MEBENDAZOLE [USAN];Pharmakon1600-01501110;AKOS000539066;BPBio1_000257;HMS2095L15;Sufil;NSC 184849;5-Benzoyl-2-benzimidazolylcarbamicacidmethylester;Cambridge id 5250893;MEBENDAZOLE [USP MONOGRAPH];NCGC00016806-01;MEBENDAZOLE [EP MONOGRAPH];MEBENDAZOLE [JAN];Mebendazole for system suitability;CCG-39628;NCGC00016806-04;D70118;KBio1_000751;BIDD:GT0087;NCGC00016806-05;R-17635;HMS1536H11;Mebendazole [USAN:USP:INN:BAN:JAN];N-(Benzoyl-5, benzimidazolyl)-2, carbamate de methyle [French];IDI1_000751;MEBENDAZOLE [USP-RS];AG-205/04588045;MEBENDAZOLE [USP IMPURITY];A820852;TimTec1_000869;Prestwick3_000217;Mebenoazole;CAS-31431-39-7;2-Benzimidazolecarbamic acid, 5-benzoyl-, methyl ester (8CI);CPD000036734;Methyl N-(5-benzoyl-1H-benzimidazol-2-yl)carbamate;NCGC00016806-02;Vermirax;MEBENDAZOLE (USP IMPURITY);Spectrum2_001401;Probes1_000013;Methyl (6-benzoyl-1H-benzimidazol-2-yl)carbamate;5-Be... |
| CAS No. | 31431-39-7 |
| 分子式 | C16H13N3O3 |
| 分子量 | 295.29 |
4-(2-((2R,3R)-3-(2,5-二氟苯基)-3-羟基-4-(1H-1,2,4-三唑-1-基)丁-2-基)噻唑-4-基)苯甲腈
N-(丁基磺酰基)-O-[4-(4-哌啶基)丁基]-L-酪氨酸盐酸盐一水合物
2-(4-(1-羟基-4-(4-(羟基二苯基甲基)哌啶-1-基)丁基)苯基)-2-甲基丙酸
7-环戊基-N,N-二甲基-2-((5-(哌嗪-1-基)吡啶-2-基)氨基)-7H-吡咯并[2,3-d]嘧啶-6-甲酰胺
(1-((2R,3R,4S,5R)-3,4-二羟基-5-甲基四氢呋喃-2-基)-5-氟-2-氧代-1,2-二氢嘧啶-4-基)氨基甲酸戊酯
((3S,5R)-5-((1H-1,2,4-三唑-1-基)甲基)-5-(2,4-二氟苯基)四氢呋喃-3-基)甲基 4-甲基苯磺酸酯
N-(3-氯-4-氟苯基)-7-甲氧基-6-(3-吗啉-4-丙氧基)喹唑啉-4-胺
(6R,7R)-3-甲基-7-[(R)-2-氨基-2-苯乙酰氨基]-8-氧-5-硫杂-1-双环[4.2.0]辛-2-烯-2-甲酸
(2R,3S,5S)-3-苄氧基-5-[2-[[(4-甲氧基苯基)二苯基甲基]氨基]-6-苄氧基-9H-嘌呤-9-基]-2-苄氧基甲基环戊醇
(2R,3R,4S,5R)-2-(4-氨基吡咯并[2,1-F][1,2,4]三嗪-7-基)-3,4-二羟基-5-(羟甲基)四氢呋喃-2-甲腈
本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用。
CopyRight @2025 广东元丰化学试剂有限公司 版权所有 | 隐私政策 条款及条件 | 粤ICP备2025403430号-1
技术支持:库价化学